1-20 of 77
Stephen Opat
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) and continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study

Free
Constantine Tam, Talha Munir, Tadeusz Robak, Jennifer Brown, Brad Kahl, Paolo Ghia, Stephen Opat, Patricia Walker, Masa Lasica, Ian Flinn, Jiayi Shen, Nataliya Kuptsova-Clarkson, Marcus Lefebure, Jamie Hirata, Wojciech Jurczak, Mazyar Shadman
Journal: Blood
Blood (2025) 146 (Supplement 1): 2129.
https://doi.org/10.1182/blood-2025-2129
Published: 2025
Journal Articles

Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial

Free
Hyun Yong Jin, Jeff Sharman, Luca Laurenti, Emmanuelle Ferrant, Luis Felipe Casado Montero, Stephen Mulligan, Rosemary Harrup, Stephen Opat, Adalberto Ibatici, Roberto Marasca, Paolo Sportoletti, Archie Egginton, Maria Thadani-Mulero, Oscar Cazarez, Yanwen Jiang, Michelle Boyer, Franck Morschhauser
Journal: Blood
Blood (2025) 146 (Supplement 1): 682.
https://doi.org/10.1182/blood-2025-682
Published: 2025
Journal Articles

Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study

Free
Constantine Tam, Mary Ann Anderson, Masa Lasica, Emma Verner, Stephen Opat, Shuo Ma, Robert Weinkove, Raul Cordoba, Jacob Soumerai, Paolo Ghia, Sophie Leitch, David Westerman, Sheel Patel, Yiqian Fang, James Hilger, Remus Vezan, Chan Cheah
Journal: Blood
Blood (2025) 146 (Supplement 1): 3891.
https://doi.org/10.1182/blood-2025-3891
Published: 2025
Journal Articles

Zanubrutinib + obinutuzumab + sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL): Initial results from an ongoing phase 1/1b study, BGB-11417-101

Free
Jacob Soumerai, Stephen Opat, Chan Cheah, Mazyar Shadman, Emma Verner, Monica Tani, Marc Hoffmann, Lori Leslie, Shuo Ma, Yiqian Fang, Gabriel Man, Binghao Wu, Charity Henrich, Sheel Patel, Remus Vezan, Constantine Tam
Journal: Blood
Blood (2025) 146 (Supplement 1): 3890.
https://doi.org/10.1182/blood-2025-3890
Published: 2025
Journal Articles

Trial in progress: Treatment of CNS lymphoma with zanubrutinib and tislelizumab: A phase ib/II investigator-initiated study

Free
Ross Salvaris, Colm Keane, Judith Trotman, Antony Sutherland, Mark Waltham, David Simpson, Gareth P. Gregory, Stephen Opat
Journal: Blood
Blood (2025) 146 (Supplement 1): 1926.
https://doi.org/10.1182/blood-2025-1926
Published: 2025
Journal Articles

Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma

Free
Fei Li, Stephen Opat, Dengju Li, Keshu Zhou, Peng Liu, Wei Yang, Chan Cheah, Tingyu Wang, Yu Yang, Caixia Li, Hongmei Jing, Henry Ngu, Lipeng Chen, Ting Deng, Fangjie Xie, Naisargee Shah, Zhao Xu, Richard Delarue, Jianyong Li
Journal: Blood
Blood (2025) 146 (Supplement 1): 1910.
https://doi.org/10.1182/blood-2025-1910
Published: 2025
Journal Articles

An international view on the current approaches to frontline chronic lymphocytic leukemia therapy

Free
Guilherme Perini, Ahmad Alhuraiji, Mary Ann Anderson, Gilberto Israel Barranco Lampón, Otavio Cesar Carvalho Guimarães Baiocchi, Ahmet Emre Eskazan, Yeow Tee Goh, Wei-Han Huang, Mervat Mattar, Evgeny Nikitin, Stephen Opat, Miguel Pavlovsky, Wei Xu
Journal: Blood
Blood (2025) 146 (Supplement 1): 7937.
https://doi.org/10.1182/blood-2025-7937
Published: 2025
Journal Articles

MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: Initial results from an ongoing phase 1/1b study, BGB-11417-101

Free
Marc Hoffmann, Shuo Ma, Herbert Eradat, Constantine Tam, Masa Lasica, Paul Hampel, Emma Verner, Lori Leslie, Christopher D'Angelo, Jacob Soumerai, Mazyar Shadman, Chan Cheah, Monica Tani, Yiqian Fang, Binghao Wu, Gabriel Man, Sheel Patel, Remus Vezan, Stephen Opat
Journal: Blood
Blood (2025) 146 (Supplement 1): 793.
https://doi.org/10.1182/blood-2025-793
Published: 2025
Journal Articles

CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations

Free
Jeff P. Sharman, Luca Laurenti, Emmanuelle Ferrant, Luis Felipe Casado Montero, Stephen P Mulligan, Rosemary Harrup, Stephen Opat, Adalberto Ibatici, Roberto Marasca, Paolo Sportoletti, Marcus Lefebure, Michelle Boyer, Yanwen Jiang, Simona Barlera, Oscar Cazares, Franck Morschhauser
Journal: Blood
Blood (2024) 144 (Supplement 1): 3237.
https://doi.org/10.1182/blood-2024-200632
Published: 2024
Journal Articles

Reduction of Tumor Lysis Syndrome Risk after Debulking with Obinutuzumab in Patients Treated with Venetoclax-Obinutuzumab in the Randomized Phase 3 CRISTALLO Trial

Free
Paolo Sportoletti, Luca Laurenti, Emmanuelle Ferrant, Luis Felipe Casado Montero, Stephen P Mulligan, Rosemary Harrup, Stephen Opat, Adalberto Ibatici, Roberto Marasca, Marcus Lefebure, Michelle Boyer, Yanwen Jiang, Simona Barlera, Oscar Cazares, Franck Morschhauser, Jeff P. Sharman
Journal: Blood
Blood (2024) 144 (Supplement 1): 1873.
https://doi.org/10.1182/blood-2024-198372
Published: 2024
Journal Articles

Treatment of relapsed CLL “in the BAAG”?

Free
Stephen Opat
Journal: Blood
Blood (2024) 144 (3): 243–244.
https://doi.org/10.1182/blood.2024024790
Published: 2024
Journal Articles

Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Receiving Ibrutinib on the Phase 3 ASPEN Study ≥1 Year After Transitioning to Zanubrutinib

Free
Ramon Garcia-Sanz, Roger Owen, Wojciech Jurczak, Meletios A. Dimopoulos, Helen McCarthy, Gavin Cull, Stephen Opat, Jorge J. Castillo, Marie José Kersten, Björn E. Wahlin, Sebastian Grosicki, Radha Prathikanti, Tian Tian, Heather Allewelt, Aileen Cleary Cohen, Constantine S. Tam
Journal: Blood
Blood (2023) 142 (Supplement 1): 3043.
https://doi.org/10.1182/blood-2023-174294
Published: 2023
Journal Articles

Development and Validation of the Early-Stage Hodgkin Lymphoma (HL) International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Free
Andrew M Evens, Angie Mae Rodday, Matthew J. Maurer, Ranjana H. Advani, Marc Andre, Andrea Gallamini, Annette E. Hay, David Hodgson, Richard T. Hoppe, Martin Hutchings, Peter Johnson, Brian K. Link, Stephen Opat, John M. Raemaekers, Jenica Upshaw, Qingyan Xiang, Nicholas Counsell, Susan K Parsons, John Radford
Journal: Blood
Blood (2023) 142 (Supplement 1): 3058.
https://doi.org/10.1182/blood-2023-173320
Published: 2023
Journal Articles

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with CLL/SLL: Preliminary Data

Free
Chan Y. Cheah, Constantine S. Tam, Masa Lasica, Emma Verner, Peter J. Browett, Mary Ann Anderson, James Hilger, Yiqian Fang, David Simpson, Stephen Opat
Journal: Blood
Blood (2022) 140 (Supplement 1): 2321–2323.
https://doi.org/10.1182/blood-2022-169662
Published: 2022
Journal Articles

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study

Free
Laurie H. Sehn, Mark Hertzberg, Stephen Opat, Alex F. Herrera, Sarit Assouline, Christopher R. Flowers, Tae Min Kim, Andrew K. McMillan, Muhit Özcan, Violaine Safar, Gilles Salles, Jamie Hirata, Annie Yang, Lisa Musick, Matthew J. Matasar
Journal: Blood
Blood (2022) 140 (Supplement 1): 9464–9467.
https://doi.org/10.1182/blood-2022-157679
Published: 2022
Journal Articles

Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

Free
John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Bryone J. Kuss, Xavier C. Badoux, Jacqueline C. Barrientos, Alessandra Tedeschi, Stephen Opat, Ian W. Flinn, Eva Gonzalez Barca, Ryan Jacobs, Edith Szafer-Glusman, Cathy Zhou, Anita Szoke, William G. Wierda, Paolo Ghia, Constantine S. Tam
Journal: Blood
Blood (2022) 140 (Supplement 1): 224–227.
https://doi.org/10.1182/blood-2022-160338
Published: 2022
Journal Articles

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Free
Stephen Opat, Alessandra Tedeschi, Bei Hu, Kim M. Linton, Pamela McKay, Henry Chan, Jie Jin, Mingyuan Sun, Magdalena Sobieraj-Teague, Pier Luigi Zinzani, Peter J. Browett, Xiaoyan Ke, Craig A. Portell, Catherine Thieblemont, Kirit Ardeshna, Fontanet Bijou, Patricia Walker, Eliza Hawkes, Shir-Jing Ho, Keshu Zhou, Zhiyu Liang, Jianfeng Xu, Chris Tankersley, Richard Delarue, Melannie Co, Judith Trotman
Journal: Blood
Blood (2022) 140 (Supplement 1): 573–576.
https://doi.org/10.1182/blood-2022-163371
Published: 2022
Journal Articles

Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis

Free
Yuqin Song, Keshu Zhou, Dehui Zou, Dengju Li, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Daobin Zhou, Constantine S. Tam, David Simpson, Michael L. Wang, Tycel J. Phillips, Stephen Opat, Cheng Fang, Shaohui Sun, Jun Zhu
Journal: Blood
Blood (2022) 140 (Supplement 1): 6501–6503.
https://doi.org/10.1182/blood-2022-162135
Published: 2022
Journal Articles

A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data

Free
Jacob D. Soumerai, Masa Lasica, Stephen Opat, Chan Y. Cheah, Henry Chan, Emma Verner, Eva González Barca, Alessandra Tedeschi, James Hilger, Yiqian Fang, David Simpson, Constantine S. Tam
Journal: Blood
Blood (2022) 140 (Supplement 1): 9325–9327.
https://doi.org/10.1182/blood-2022-169664
Published: 2022
Journal Articles

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Open Access
Clinical Trials & Observations
Constantine S. Tam, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Ryan Jacobs, Stephen Opat, Paul M. Barr, Alessandra Tedeschi, Livio Trentin, Rajat Bannerji, Sharon Jackson, Bryone J. Kuss, Carol Moreno, Edith Szafer-Glusman, Kristin Russell, Cathy Zhou, Joi Ninomoto, James P. Dean, William G. Wierda, Paolo Ghia
Journal: Blood
Blood (2022) 139 (22): 3278–3289.
https://doi.org/10.1182/blood.2021014488
Published: 2022
Includes: Supplemental data